Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference
TAMPA, Fla., March 09, 2022 — Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 10:15 AM ET in Miami.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TAMPA, Fla., March 09, 2022 — Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 10:15 AM ET in Miami. Investors can listen to the live audio via the company's Events page, with a replay available for two weeks post-event. Pacira focuses on non-opioid treatments, offering products like EXPAREL for postsurgical pain management and ZILRETTA for osteoarthritis knee pain, aiming to reduce opioid reliance.
Details
News Market Reaction – PCRX
The recorded move for PCRX in the trading session of this news was +2.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 10:15 AM ET on Wednesday, March 16, 2022 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.